MX386181B - Formas cristalinas de un inhibidor de quinasa janus - Google Patents

Formas cristalinas de un inhibidor de quinasa janus

Info

Publication number
MX386181B
MX386181B MX2019007462A MX2019007462A MX386181B MX 386181 B MX386181 B MX 386181B MX 2019007462 A MX2019007462 A MX 2019007462A MX 2019007462 A MX2019007462 A MX 2019007462A MX 386181 B MX386181 B MX 386181B
Authority
MX
Mexico
Prior art keywords
crystalline forms
janus kinase
kinase inhibitor
methods
inhibitor
Prior art date
Application number
MX2019007462A
Other languages
English (en)
Other versions
MX2019007462A (es
Inventor
Noriaki Shimoyama
Ryuhei Okura
Satoru Noji
Yukihiro Kamiya
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2019007462A publication Critical patent/MX2019007462A/es
Publication of MX386181B publication Critical patent/MX386181B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a formas cristalinas del inhibidor de la quinasa Janus (JAK) 3-((3S,4R)-3-metil-6-(7H-pirrolo[2,3-d]pirimidin-4-il)-1,6-diazaspiro[3.4]octan-1-il)-3-oxopropanenitrilo (Compuesto A), así como, sus composiciones, métodos de su preparación, métodos de su uso y método de cuantificación.
MX2019007462A 2016-12-21 2017-12-20 Formas cristalinas de un inhibidor de quinasa janus MX386181B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662437262P 2016-12-21 2016-12-21
PCT/JP2017/045731 WO2018117153A1 (en) 2016-12-21 2017-12-20 Crystalline forms of a janus kinase inhibitor

Publications (2)

Publication Number Publication Date
MX2019007462A MX2019007462A (es) 2019-08-29
MX386181B true MX386181B (es) 2025-03-18

Family

ID=60991475

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007462A MX386181B (es) 2016-12-21 2017-12-20 Formas cristalinas de un inhibidor de quinasa janus

Country Status (13)

Country Link
US (1) US11339181B2 (es)
EP (1) EP3559003B1 (es)
JP (3) JP2020502224A (es)
KR (1) KR102788829B1 (es)
CN (2) CN121045220A (es)
AU (1) AU2017380213B2 (es)
BR (1) BR112019012210A2 (es)
CA (1) CA3044771A1 (es)
ES (1) ES2926986T3 (es)
IL (1) IL267393B2 (es)
MX (1) MX386181B (es)
TW (1) TWI822666B (es)
WO (1) WO2018117153A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110300756B (zh) 2016-12-21 2024-01-02 日本烟草产业株式会社 7H-吡咯并[2,3-d]嘧啶衍生物的制备方法及其合成中间体
CN114173788A (zh) * 2019-08-07 2022-03-11 乐敦制药株式会社 泪液分泌促进用眼科组合物
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
CA3224068A1 (en) * 2021-07-30 2023-02-02 Eli Lilly And Company Treatment of hand eczema with baricitinib
AU2024229918A1 (en) 2023-02-28 2025-09-18 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
WO2024225445A1 (en) * 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908280A2 (fr) * 2005-07-07 2008-04-09 THOMSON Licensing Systeme d'affichage a ecran plat et fourreaux correspondant
EP2108641A1 (en) * 2008-04-11 2009-10-14 Laboratorios Almirall, S.A. New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors
JP6172939B2 (ja) * 2009-05-22 2017-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害薬としての３−［４−（７ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１ｈ−ピラゾール−１−イル］オクタン−またはヘプタン−ニトリル
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) * 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
HK1251223A1 (en) * 2015-07-07 2019-01-25 Japan Tobacco, Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof

Also Published As

Publication number Publication date
EP3559003A1 (en) 2019-10-30
RU2019122566A3 (es) 2021-12-22
TWI822666B (zh) 2023-11-21
ES2926986T3 (es) 2022-10-31
JP2024161449A (ja) 2024-11-19
IL267393A (en) 2019-08-29
TW201829423A (zh) 2018-08-16
AU2017380213A1 (en) 2019-05-23
IL267393B1 (en) 2023-03-01
CN110325536A (zh) 2019-10-11
US20200017527A1 (en) 2020-01-16
US11339181B2 (en) 2022-05-24
MX2019007462A (es) 2019-08-29
CN121045220A (zh) 2025-12-02
AU2017380213B2 (en) 2022-01-06
IL267393B2 (en) 2023-07-01
JP2020502224A (ja) 2020-01-23
BR112019012210A2 (pt) 2019-11-12
CA3044771A1 (en) 2018-06-28
JP2023024729A (ja) 2023-02-16
KR102788829B1 (ko) 2025-03-31
RU2019122566A (ru) 2021-01-22
WO2018117153A1 (en) 2018-06-28
EP3559003B1 (en) 2022-08-24
KR20190092440A (ko) 2019-08-07

Similar Documents

Publication Publication Date Title
MX386181B (es) Formas cristalinas de un inhibidor de quinasa janus
MX2017016772A (es) Metodo para producir un derivado de 7h-pirrolo[2,3-d]pirimidina e intermediario del mismo.
PH12019500393A1 (en) Substituted pyrrolizine compounds and uses thereof
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
CL2019000942A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
MX2024005335A (es) Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos.
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12020500201A1 (en) Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
UY35861A (es) ?acrilamidas de pirrolo[2,3-d]pirimidini lo, pirrolo[2,3-b]irazinilo y pirrolo[2,3-d]piridinilo?
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
EA201400701A1 (ru) Замещенные соединения пиразоло[1,5-a]пиридина в качестве ингибиторов тропомиозинрецепторной киназы (trk)
NZ744349A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
EA201791274A1 (ru) ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV)
WO2010121576A3 (en) Novel 7-deazapurine nucleosides for therapeutic uses
WO2016063294A3 (en) Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof
MX2019007452A (es) Proceso para preparar derivados de 7h-pirrolo[2,3-d]pirimidina y co-cristales de los mismos.
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
AU2017319080A1 (en) Pyrazolo[1,5-a]pyrimidine compound
EP3196199A4 (en) Substituted n-(pyrrolidine-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine as janus kinase inhibitor
WO2018166993A3 (en) PYRAZOLOCHLOROPHENYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
JOP20190080A1 (ar) مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
EA201791276A1 (ru) Замещенные пиперидином трициклические производные пиразоло[1,5-a]пиримидина с ингибирующей активностью в отношении репликации респираторно-синцитиального вируса (rsv)
MX2017003415A (es) Un derivado de tetrahidropirrolo [3,4-d] [1,3]tiazina como inhibidor de bace.